Literature DB >> 10395051

Low seroprevalence of HTLV-I and HTLV-II in patients with a sexually transmitted disease. Study Group for HTLV and STDs.

B Suligoi1, C Galli, S Ciuta, R Decker.   

Abstract

To determine the prevalence of HTLV I-II among highly sexually active adults, a seroprevalence study was conducted in Italy between March 1992 and March 1993 among 1506 patients with a newly diagnosed STD. Individuals were tested with an enzyme immunoassay that employs a double viral lysate from HTLV-I and HTLV-II infected cell lines; confirmation and discrimination between HTLV-I and II were performed by a dot-blot immunoassay. One patient (0.07%) was confirmed HTLV-I positive and one (0.07%) HTLV-II positive. The HTLV-I positive was a Romanian woman, and the other was an intravenous drug user. The 0.13% HTLV prevalence observed in this study is intermediate between the 0.034% found among Italian blood donors and the 3.5-6% found among Italian intravenous drug users. These data suggest that there is not a high prevalence of these viruses among Italians with STDs.

Entities:  

Mesh:

Year:  1999        PMID: 10395051     DOI: 10.1023/a:1007534600034

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  24 in total

1.  Seropositivity for HTLV-1 among Italian prisoners.

Authors:  G Marinucci; C Di Giacomo; A Dato; F Ceralli; M Taborchi; C Galli; M Canavaggio; H Lee
Journal:  AIDS       Date:  1990-09       Impact factor: 4.177

2.  Incidence of HIV and HTLV-1 infection among sexually transmitted disease clinic attenders in Jamaica.

Authors:  J P Figueroa; E Ward; J Morris; A R Brathwaite; A Peruga; W Blattner; S H Vermund; R Hayes
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-07-01

3.  Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21E antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms.

Authors:  T M Hartley; G E Malone; R F Khabbaz; R B Lal; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

4.  Sexual transmission of human T-lymphotropic virus type I (HTLV-I).

Authors:  E L Murphy; J P Figueroa; W N Gibbs; A Brathwaite; M Holding-Cobham; D Waters; B Cranston; B Hanchard; W A Blattner
Journal:  Ann Intern Med       Date:  1989-10-01       Impact factor: 25.391

5.  Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors.

Authors:  H H Lee; P Swanson; J D Rosenblatt; I S Chen; W C Sherwood; D E Smith; G E Tegtmeier; L P Fernando; C T Fang; M Osame
Journal:  Lancet       Date:  1991-06-15       Impact factor: 79.321

6.  A multicentric seroepidemiological survey of HTLV-I/II in Italy.

Authors:  H H Lee; C Galli; J D Burczak; F Biffoni; G De Stasio; S De Virgiliis; G Fanetti; M E Lai; E Mannella; G Marinucci; G Ongaro; G Zehender; A R Zanetti
Journal:  Clin Diagn Virol       Date:  1994-06

7.  Chronic neurodegenerative disease associated with HTLV-II infection.

Authors:  B Hjelle; O Appenzeller; R Mills; S Alexander; N Torrez-Martinez; R Jahnke; G Ross
Journal:  Lancet       Date:  1992-03-14       Impact factor: 79.321

8.  Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group.

Authors:  J E Kaplan; R F Khabbaz; E L Murphy; S Hermansen; C Roberts; R Lal; W Heneine; D Wright; L Matijas; R Thomson; D Rudolph; W M Switzer; S Kleinman; M Busch; G B Schreiber
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-06-01

9.  Screening for anti-human T-lymphotropic virus antibody in blood donors and polytransfused patients in Apulia (Italy).

Authors:  G de Stasio; M Canavaggio; L Rizzi; A Lattanzio; M Lancieri; F D'Erasmo; A Colapietro; S Barbuti; M Quarto; V Liso
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.